Document Classification

Section Type: RESULTS

Text: Among patients who had a stent placed before or at the time of the index event, rivaroxaban significantly reduced independently adjudicated Academic Research Consortium definite and probable stent thrombosis in the pooled (1. 9 % vs. 1. 5 % ; hazard ratio [HR] : 0. 65 ; p = 0. 017) and the 2. 5 mg twice-daily (1. 9 % vs. 1. 5 % ; HR : 0. 61 ; p = 0. 023) treatment groups when compared with placebo, with a trend toward a reduction in the 5 mg twice-daily treatment group (1. 9 % vs. 1. 5 % ; HR : 0. 70 ; p = 0. 089).